These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38060600)

  • 1. How does equity restriction affect innovation quality? Evidence from listed manufacturing companies in China.
    Chang S; Wu J; Riaz M; Hu Z
    PLoS One; 2023; 18(12):e0295553. PubMed ID: 38060600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Executive pharmaceutical background, R&D investment and corporate innovation performance.
    Zhang L; Li S; Wu M
    Am J Transl Res; 2023; 15(11):6576-6586. PubMed ID: 38074834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Managerial Reputation and Risk-Taking on Enterprise Innovation Investment From the Perspective of Social Capital: Evidence From China.
    Wang S; Zhao S; Shao D; Fan X; Zhang B
    Front Psychol; 2022; 13():931227. PubMed ID: 35874409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corporate governance, technological innovation, and corporate performance: Evidence from China.
    Ma Y; Binti A Rahim NS; Bt Panatik SA; Li R
    Heliyon; 2024 Jun; 10(11):e31459. PubMed ID: 38828300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Firms' digitalization in manufacturing and the structure and direction of green innovation.
    Liu X; Liu F; Ren X
    J Environ Manage; 2023 Jun; 335():117525. PubMed ID: 36812685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enterprise innovation and audit pricing: An evidence study from China's A-share listed companies.
    Zhang L; Su W; Liu S
    PLoS One; 2024; 19(3):e0300137. PubMed ID: 38466695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Research on the Effect of Executive Incentive Institutional Innovation on the Cost of Equity-Evidence From Chinese Listed Companies.
    Wang J; Deng J
    Front Psychol; 2021; 12():686955. PubMed ID: 34168600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tax incentives and environmental, social, and governance performance: empirical evidence from China.
    Zhu N; Zhou Y; Zhang S; Yan J
    Environ Sci Pollut Res Int; 2023 Apr; 30(19):54899-54913. PubMed ID: 36881223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Mixed-Ownership Reform on Innovation Performance of Manufacturing Companies: Evidence from China.
    Xia W; Chen X; Wang G
    Comput Intell Neurosci; 2022; 2022():3809829. PubMed ID: 35785061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promote Green Innovation in Manufacturing Enterprises in the Aspect of Government Subsidies in China.
    Sun X; Tang J; Li S
    Int J Environ Res Public Health; 2022 Jun; 19(13):. PubMed ID: 35805523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Qualified foreign institutional investors and corporate innovation: From the perspective of corporate governance.
    Wang X; Wang W; Shi XY
    Front Psychol; 2022; 13():1005409. PubMed ID: 36467163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Business Model Innovation Paths of Manufacturing Oriented towards Green Development in Digital Economy.
    Han X; Zhang J
    Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does environmental governance matter to the relationship between digital transformation and high-quality development? Evidence from manufacturing sector in China.
    Sun W; Fang J
    Environ Sci Pollut Res Int; 2023 Sep; 30(43):97005-97024. PubMed ID: 37584795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital transformation and innovation output of manufacturing companies-An analysis of the mediating role of internal and external transaction costs.
    Meng X; Gong X
    PLoS One; 2024; 19(1):e0296876. PubMed ID: 38241293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of corporate digital strategic orientation on innovation output.
    Fan X; Zhao S; Zhang B; Wang S; Shao D
    Heliyon; 2023 May; 9(5):e16371. PubMed ID: 37251887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Correlation between Enterprise Internal Control Quality and Research and Development Investment Intensity.
    Hu S; Yang H
    Comput Intell Neurosci; 2022; 2022():1788142. PubMed ID: 35785049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Will China's R&D investment improve green innovation performance? An empirical study.
    Fan J; Teo T
    Environ Sci Pollut Res Int; 2022 Jun; 29(26):39331-39344. PubMed ID: 35099703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoting and inhibiting: Corporate charitable donations and innovation investment under different motivation orientations--Evidence from Chinese listed companies.
    Wang H; Zhang Y; Tian M; Wang Z; Ding Y
    PLoS One; 2022; 17(4):e0266199. PubMed ID: 35417498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of R&D innovation and political background on corporate growth: A study based on private listed companies in China.
    Kong X; Chen H; Wu P; Ma R; Pan F
    PLoS One; 2024; 19(5):e0297329. PubMed ID: 38723045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does CSR affect the cost of equity capital: Empirical evidence from the targeted poverty alleviation of listed companies in China.
    Yi Y; Xie B; Zhou L; Wei Y
    PLoS One; 2020; 15(2):e0227952. PubMed ID: 32032381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.